John Farah
Direttore/Membro del Consiglio presso AEOLUS PHARMACEUTICALS, INC.
Patrimonio netto: 1 339 $ in data 30/06/2024
Posizioni attive di John Farah
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| AEOLUS PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 24/10/2005 | - |
| Independent Dir/Board Member | 23/05/2011 | - | |
| POND TECHNOLOGIES HOLDINGS INC. | Direttore/Membro del Consiglio | 14/07/2021 | - |
Storia della carriera di John Farah
Precedenti posizioni note di John Farah
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Cephalon, Inc.
 Cephalon, Inc. Pharmaceuticals: MajorHealth Technology Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA. | Corporate Officer/Principal | 01/10/1992 | - |
| REBUS HOLDINGS, INC. | Direttore/Membro del Consiglio | 01/02/2008 | 17/08/2010 |
| Independent Dir/Board Member | 01/02/2008 | 17/08/2010 | |
Melior Discovery, Inc.
 Melior Discovery, Inc. Miscellaneous Commercial ServicesCommercial Services Melior Discovery, Inc. provides phenotypic screening, in vivo pharmacology, drug abuse liability and seizure potential services. It offers theraTRACE, an indications discovery platform of multiplexed in vivo models that focus on various indications/therapeutic areas, including neurodegenerative disease and psychiatry, inflammation, acute and chronic pain, metabolic disease, gastrointestinal & urology, cardiovascular disease, and dermatology aspects. The company was founded by Andrew G. Reaume and Michael S. Saporito in 2005 and is headquartered in Exton, PA. | Direttore/Membro del Consiglio | 11/01/2013 | 16/01/2013 |
| Independent Dir/Board Member | 11/01/2013 | 16/01/2013 | |
| Corporate Officer/Principal | 16/01/2013 | - | |
G.D. Searle & Co., Inc.
 G.D. Searle & Co., Inc. Chemicals: SpecialtyProcess Industries G.D. Searle & Co., Inc. is a company that produces a diverse range of chemicals and agricultural products. The company is based in St. Louis, MO. G.D. Searle & Co. was acquired by Monsanto Co. /Old/ on January 01, 1985. | Direttore Tecnico/Scientifico/R&S | - | - |
Formazione di John Farah
| University of Maryland | Undergraduate Degree |
| New College of California | Undergraduate Degree |
| Uniformed Services University of the Health Sciences | Doctorate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 9 |
| Canada | 2 |
Posizioni
| Director/Board Member | 4 |
| Independent Dir/Board Member | 3 |
| Undergraduate Degree | 2 |
Settori
| Health Technology | 5 |
| Consumer Services | 4 |
| Process Industries | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| AEOLUS PHARMACEUTICALS, INC. | Health Technology |
| REBUS HOLDINGS, INC. | Health Technology |
| POND TECHNOLOGIES HOLDINGS INC. | Health Technology |
| Aziende private | 3 |
|---|---|
G.D. Searle & Co., Inc.
G.D. Searle & Co., Inc. Chemicals: SpecialtyProcess Industries G.D. Searle & Co., Inc. is a company that produces a diverse range of chemicals and agricultural products. The company is based in St. Louis, MO. G.D. Searle & Co. was acquired by Monsanto Co. /Old/ on January 01, 1985. | Process Industries |
Cephalon, Inc.
Cephalon, Inc. Pharmaceuticals: MajorHealth Technology Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA. | Health Technology |
Melior Discovery, Inc.
Melior Discovery, Inc. Miscellaneous Commercial ServicesCommercial Services Melior Discovery, Inc. provides phenotypic screening, in vivo pharmacology, drug abuse liability and seizure potential services. It offers theraTRACE, an indications discovery platform of multiplexed in vivo models that focus on various indications/therapeutic areas, including neurodegenerative disease and psychiatry, inflammation, acute and chronic pain, metabolic disease, gastrointestinal & urology, cardiovascular disease, and dermatology aspects. The company was founded by Andrew G. Reaume and Michael S. Saporito in 2005 and is headquartered in Exton, PA. | Commercial Services |
- Borsa valori
- Insiders
- John Farah
- Esperienza
